Literature DB >> 19494155

Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Michael S Virk1, Seksiri Arttamangkul, William T Birdsong, John T Williams.   

Abstract

Buprenorphine is a weak partial agonist at mu-opioid receptors that is used for treatment of pain and addiction. Intracellular and whole-cell recordings were made from locus ceruleus neurons in rat brain slices to characterize the actions of buprenorphine. Acute application of buprenorphine caused a hyperpolarization that was prevented by previous treatment of slices with the irreversible opioid antagonist beta-chlornaltrexamine (beta-CNA) but was not reversed by a saturating concentration of naloxone. As expected for a partial agonist, subsaturating concentrations of buprenorphine decreased the [Met](5)enkephalin (ME)-induced hyperpolarization or outward current. When the ME-induced current was decreased below a critical value, desensitization and internalization of mu-opioid receptors was eliminated. The inhibition of desensitization by buprenorphine was not the result of previous desensitization, slow dissociation from the receptor, or elimination of receptor reserve. Treatment of slices with subsaturating concentrations of etorphine, methadone, oxymorphone, or beta-CNA also reduced the current induced by ME but did not block ME-induced desensitization. Treatment of animals with buprenorphine for 1 week resulted in the inhibition of the current induced by ME and a block of desensitization that was not different from the acute application of buprenorphine to brain slices. These observations show the unique characteristics of buprenorphine and further demonstrate the range of agonist-selective actions that are possible through G-protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494155      PMCID: PMC2752300          DOI: 10.1523/JNEUROSCI.3723-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  46 in total

1.  Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

Authors:  P Huang; G B Kehner; A Cowan; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

2.  Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?

Authors:  P A Zaki; D E Keith; G A Brine; F I Carroll; C J Evans
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor.

Authors:  P Bloms-Funke; C Gillen; A J Schuettler; S Wnendt
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

4.  Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats.

Authors:  E A Walker; A M Young
Journal:  Psychopharmacology (Berl)       Date:  2001-03-01       Impact factor: 4.530

Review 5.  Opioid dependence treatment, including buprenorphine/naloxone.

Authors:  Dennis W Raisch; Carol L Fye; Kathy D Boardman; Mike R Sather
Journal:  Ann Pharmacother       Date:  2002-02       Impact factor: 3.154

6.  Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor.

Authors:  P Y Law; L J Erickson; R El-Kouhen; L Dicker; J Solberg; W Wang; E Miller; A L Burd; H H Loh
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

7.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.

Authors:  R E Johnson; M A Chutuape; E C Strain; S L Walsh; M L Stitzer; G E Bigelow
Journal:  N Engl J Med       Date:  2000-11-02       Impact factor: 91.245

8.  A meta-analysis comparing the effectiveness of buprenorphine and methadone.

Authors:  S L West; K K O'Neal; C W Graham
Journal:  J Subst Abuse       Date:  2000

9.  Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay.

Authors:  S Wnendt; T Krüger; E Janocha; D Hildebrandt; W Englberger
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

Review 10.  Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction.

Authors:  Thomas M Tzschentke
Journal:  Psychopharmacology (Berl)       Date:  2002-03-06       Impact factor: 4.530

View more
  22 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

Review 3.  Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons.

Authors:  Vu C Dang; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Antinociceptive effects of sustained-release buprenorphine in a model of incisional pain in rats (Rattus norvegicus).

Authors:  Helen H Chum; Katechan Jampachairsri; Gabriel P McKeon; David C Yeomans; Cholawat Pacharinsak; Stephen A Felt
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-03       Impact factor: 1.232

5.  A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro.

Authors:  Alisa Knapman; Marina Santiago; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

6.  Desensitization and Tolerance of Mu Opioid Receptors on Pontine Kölliker-Fuse Neurons.

Authors:  Erica S Levitt; John T Williams
Journal:  Mol Pharmacol       Date:  2017-11-02       Impact factor: 4.436

7.  Desensitization of functional µ-opioid receptors increases agonist off-rate.

Authors:  John T Williams
Journal:  Mol Pharmacol       Date:  2014-04-18       Impact factor: 4.436

8.  Analgesic Activity of Tramadol and Buprenorphine after Voluntary Ingestion by Rats (Rattus norvegicus).

Authors:  Bryan F Taylor; Harvey E Ramirez; August H Battles; Karl A Andrutis; John K Neubert
Journal:  J Am Assoc Lab Anim Sci       Date:  2016-01       Impact factor: 1.232

9.  Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants.

Authors:  Steven G Grinnell; Michael Ansonoff; Gina F Marrone; Zhigang Lu; Ankita Narayan; Jin Xu; Grace Rossi; Susruta Majumdar; Ying-Xian Pan; Daniel L Bassoni; John Pintar; Gavril W Pasternak
Journal:  Synapse       Date:  2016-07-12       Impact factor: 2.562

10.  Does PKC activation increase the homologous desensitization of μ opioid receptors?

Authors:  Seksiri Arttamangkul; William Birdsong; John T Williams
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.